Lantheus (NASDAQ:LNTH – Get Rating) had its target price upped by equities researchers at SVB Leerink from $100.00 to $110.00 in a research report issued on Friday, Benzinga reports. The firm currently has an "outperform" rating on the medical equipment provider's stock. SVB Leerink's target price indicates a potential upside of 44.70% from the stock's current price.

Other equities research analysts also recently issued reports about the company. Truist Financial raised their price target on Lantheus from $77.00 to $94.00 in a research report on Monday, May 2nd. B. Riley began coverage on Lantheus in a research report on Monday, May 9th. They issued a "buy" rating and a $91.00 price target on the stock.

Lantheus Stock Up 6.7 %

Lantheus stock traded up $4.78 during mid-day trading on Friday, hitting $76.02. 26,297 shares of the company's stock were exchanged, compared to its average volume of 1,226,595. The company has a current ratio of 1.83, a quick ratio of 1.64 and a debt-to-equity ratio of 0.31. The stock has a market cap of $5.22 billion, a P/E ratio of -133.11 and a beta of 0.79. Lantheus has a 1-year low of $22.20 and a 1-year high of $81.43. The stock has a 50 day moving average of $67.69 and a two-hundred day moving average of $55.21.

Insider Activity at Lantheus

In related news, CAO Andrea Sabens sold 1,093 shares of the stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $71.47, for a total value of $78,116.71. Following the completion of the sale, the chief accounting officer now owns 63,162 shares in the company, valued at $4,514,188.14. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Gerard Ber sold 1,277 shares of Lantheus stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $58.19, for a total value of $74,308.63. Following the completion of the transaction, the director now owns 32,703 shares in the company, valued at $1,902,987.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 1,093 shares of Lantheus stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $71.47, for a total transaction of $78,116.71. Following the completion of the transaction, the chief accounting officer now owns 63,162 shares of the company's stock, valued at approximately $4,514,188.14. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,798 shares of company stock worth $1,676,307. Company insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. increased its holdings in shares of Lantheus by 17.0% in the fourth quarter. Principal Financial Group Inc. now owns 555,077 shares of the medical equipment provider's stock valued at $16,036,000 after purchasing an additional 80,665 shares in the last quarter. Sciencast Management LP acquired a new stake in Lantheus during the 1st quarter worth $307,000. Assenagon Asset Management S.A. grew its holdings in Lantheus by 332.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 251,845 shares of the medical equipment provider's stock worth $13,930,000 after acquiring an additional 193,585 shares during the period. Congress Wealth Management LLC DE acquired a new stake in Lantheus during the 4th quarter worth $6,329,000. Finally, Ally Bridge Group NY LLC acquired a new stake in Lantheus during the 4th quarter worth $9,534,000. Institutional investors own 97.14% of the company's stock.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Read More

• Get a free copy of the StockNews.com research report on Lantheus (LNTH)
• Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
• Beyond Meat Is Not Beyond Hope, And It's Cheap
• Why Apple Could Be At All-Time Highs By Year End
• BJ's Wholesale Club Stock Has More Room to Grow
• 3 Hotel Stocks to Consider Checking into After Earnings

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.